MX2011009568A - Inhibidores de la rho cinasa. - Google Patents

Inhibidores de la rho cinasa.

Info

Publication number
MX2011009568A
MX2011009568A MX2011009568A MX2011009568A MX2011009568A MX 2011009568 A MX2011009568 A MX 2011009568A MX 2011009568 A MX2011009568 A MX 2011009568A MX 2011009568 A MX2011009568 A MX 2011009568A MX 2011009568 A MX2011009568 A MX 2011009568A
Authority
MX
Mexico
Prior art keywords
rock2
kinase inhibitors
rho kinase
rock1
inhibitors
Prior art date
Application number
MX2011009568A
Other languages
English (en)
Inventor
Alessandra Bartolozzi
Paul Sweetnam
Anthony Campbell
Bridget COLE
Hope Foudoulakis
Brian Kirk
Hemalatha Seshadri
Siya Ram
Original Assignee
Surface Logix Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Surface Logix Inc filed Critical Surface Logix Inc
Publication of MX2011009568A publication Critical patent/MX2011009568A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
    • C07D239/72—Quinazolines; Hydrogenated quinazolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Abstract

La presente invención se refiere a inhibidores de ROCK1 y ROCK2 que pueden ser selectivos para ROCK2 y a métodos para modular las propiedades farmacocinéticas y/o farmacodinámicas de dichos compuestos. También se proporcionan métodos para inhibir ROCK1 y/o ROCK2. También se proporcionan tratamientos que combinan inhibidores de ROCK1 y/o ROCK2 con estatinas.
MX2011009568A 2009-03-09 2010-03-09 Inhibidores de la rho cinasa. MX2011009568A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US15870509P 2009-03-09 2009-03-09
PCT/US2010/026656 WO2010104851A1 (en) 2009-03-09 2010-03-09 Rho kinase inhibitors

Publications (1)

Publication Number Publication Date
MX2011009568A true MX2011009568A (es) 2011-12-06

Family

ID=42728706

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2011009568A MX2011009568A (es) 2009-03-09 2010-03-09 Inhibidores de la rho cinasa.

Country Status (7)

Country Link
US (1) US20120202793A1 (es)
EP (1) EP2406236A4 (es)
JP (1) JP2012519732A (es)
AU (1) AU2010222848A1 (es)
CA (1) CA2755095A1 (es)
MX (1) MX2011009568A (es)
WO (1) WO2010104851A1 (es)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN105007939B (zh) * 2012-10-05 2018-10-19 卡德门企业有限公司 人抗vegfr-2/kdr抗体
WO2014080290A2 (en) 2012-11-21 2014-05-30 Rvx Therapeutics Inc. Cyclic amines as bromodomain inhibitors
WO2014080291A2 (en) * 2012-11-21 2014-05-30 Rvx Therapeutics Inc. Biaryl derivatives as bromodomain inhibitors
US20150297679A1 (en) * 2012-12-14 2015-10-22 The Brigham And Women's Hospital, Inc. Methods and assays relating to macrophage differentiation
CN105073744B (zh) 2012-12-21 2019-11-08 齐尼思表观遗传学有限公司 作为溴结构域抑制剂的新型杂环化合物
PT3010503T (pt) 2013-06-21 2020-06-16 Zenith Epigenetics Corp Novos inibidores bicíclicos de bromodomínios
WO2015004534A2 (en) 2013-06-21 2015-01-15 Zenith Epigenetics Corp. Novel substituted bicyclic compounds as bromodomain inhibitors
US9855271B2 (en) 2013-07-31 2018-01-02 Zenith Epigenetics Ltd. Quinazolinones as bromodomain inhibitors
US11311541B2 (en) * 2014-04-09 2022-04-26 Kadmon Corporation, Llc Treatment of GVHD
WO2016087936A1 (en) 2014-12-01 2016-06-09 Zenith Epigenetics Corp. Substituted pyridinones as bromodomain inhibitors
WO2016087942A1 (en) 2014-12-01 2016-06-09 Zenith Epigenetics Corp. Substituted pyridines as bromodomain inhibitors
US10292968B2 (en) 2014-12-11 2019-05-21 Zenith Epigenetics Ltd. Substituted heterocycles as bromodomain inhibitors
CN107406438B (zh) 2014-12-17 2021-05-14 恒翼生物医药科技(上海)有限公司 溴结构域的抑制剂
EP3283479B1 (en) * 2015-04-01 2022-12-14 Rigel Pharmaceuticals, Inc. Tgf-beta inhibitors
US11787783B2 (en) 2016-12-13 2023-10-17 Beta Therapeutics Pty Ltd Heparanase inhibitors and use thereof
CA3046997A1 (en) * 2016-12-13 2018-06-21 Beta Therapeutics Pty Ltd Heparanase inhibitors and use thereof
CN106916145B (zh) * 2017-03-06 2019-06-04 上海应用技术大学 SLx-2119的合成方法
ES2930804T3 (es) 2017-06-30 2022-12-22 Beijing Tide Pharmaceutical Co Ltd Inhibidor de proteína cinasa asociada a RHO, composición farmacéutica que lo comprende, así como método de preparación y uso del mismo
US11390609B2 (en) 2017-06-30 2022-07-19 Beijing Tide Pharmaceutical Co., Ltd. Rho-associated protein kinase inhibitor, pharmaceutical composition comprising same, and preparation method and use thereof
WO2019000683A1 (zh) 2017-06-30 2019-01-03 北京泰德制药股份有限公司 Rho相关蛋白激酶抑制剂、包含其的药物组合物及其制备方法和用途
WO2019018562A1 (en) 2017-07-19 2019-01-24 Ideaya Biosciences, Inc. AMIDO COMPOUND AS MODULATORS OF AHR
JP2020532551A (ja) 2017-09-03 2020-11-12 アンジオン バイオメディカ コーポレーション Ｒｈｏ関連コイルドコイルキナーゼ（ＲＯＣＫ）阻害剤としてのビニルヘテロ環
US11739326B2 (en) 2017-11-14 2023-08-29 Massachusetts Eye And Ear Infirmary RUNX1 inhibition for treatment of proliferative vitreoretinopathy and conditions associated with epithelial to mesenchymal transition
JP7382348B2 (ja) 2018-02-06 2023-11-16 アイディアヤ バイオサイエンシーズ，インコーポレイティド ＡｈＲモジュレータ
EP3782987A4 (en) 2018-04-18 2021-05-19 Medshine Discovery Inc. BENZOPYRAZOLE COMPOUND AS A RHO CINEMA INHIBITOR
US20210292766A1 (en) 2018-08-29 2021-09-23 University Of Massachusetts Inhibition of Protein Kinases to Treat Friedreich Ataxia
JP7252417B2 (ja) 2019-10-18 2023-04-04 メッドシャイン ディスカバリー インコーポレイテッド Ｒｈｏキナーゼ阻害剤としてのベンゾピラゾール化合物の塩形、結晶形及びその製造方法
WO2021129589A1 (zh) * 2019-12-27 2021-07-01 广东东阳光药业有限公司 Kd-025的新晶型及其制备方法
US20230257376A1 (en) * 2020-07-14 2023-08-17 Wuhan Ll Science And Technology Development Co., Ltd. Rock inhibitor, and preparation method therefor and use thereof
CN116322670A (zh) * 2020-07-22 2023-06-23 北京泰德制药股份有限公司 治疗造血干细胞移植后的移植物抗宿主病的方法
WO2022042666A1 (zh) * 2020-08-28 2022-03-03 杭州邦顺制药有限公司 选择性rock2激酶抑制剂
CN116438175A (zh) * 2020-11-11 2023-07-14 南京明德新药研发有限公司 苯并脲环衍生物及其制备方法和应用
WO2023187697A1 (en) * 2022-03-31 2023-10-05 Glenmark Life Sciences Limited Process for the preparation of belumosudil mesylate and its crystalline form

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2422377C (en) * 2000-09-15 2010-04-13 Vertex Pharmaceuticals Incorporated Pyrazole compounds useful as protein kinase inhibitors
MXPA03008658A (es) * 2001-03-23 2005-04-11 Bayer Ag Inhibidores de rho-cinasa.
US20060233902A1 (en) * 2002-02-14 2006-10-19 Kirin Beer Kabushiki Kaisha Compositions and foods for improving lipid metabolism
CR9465A (es) * 2005-03-25 2008-06-19 Surface Logix Inc Compuestos mejorados farmacocineticamente
US20100168102A9 (en) * 2005-07-11 2010-07-01 Devgen Nv Amide Derivatives as Kinase Inhibitors
EP1928861B1 (en) * 2005-09-20 2010-11-17 AstraZeneca AB 4- (ih-indazol-5-yl-amino)-quinazoline compounds as erbb receptor tyrosine kinase inhibitors for the treatment of cancer
US20080021217A1 (en) * 2006-07-20 2008-01-24 Allen Borchardt Heterocyclic inhibitors of rho kinase
WO2008054599A2 (en) * 2006-09-27 2008-05-08 Surface Logix, Inc. Rho kinase inhibitors
JP5318779B2 (ja) * 2006-12-27 2013-10-16 サノフイ シクロアルキルアミン置換イソキノリン及びイソキノリノン誘導体

Also Published As

Publication number Publication date
WO2010104851A1 (en) 2010-09-16
AU2010222848A1 (en) 2011-10-20
US20120202793A1 (en) 2012-08-09
CA2755095A1 (en) 2010-09-16
EP2406236A4 (en) 2013-07-24
JP2012519732A (ja) 2012-08-30
EP2406236A1 (en) 2012-01-18

Similar Documents

Publication Publication Date Title
MX2011009568A (es) Inhibidores de la rho cinasa.
WO2008054599A3 (en) Rho kinase inhibitors
SG179085A1 (en) Pi3 kinase inhibitors and uses thereof
MX355728B (es) Inhibidores de cinasas.
JO2788B1 (en) Amido phenoxyendazole compounds beneficial as C-MET inhibitors
MX2010002783A (es) Proceso e intermediarios para la preparacion de inhibidores de integrasa.
HK1162022A1 (en) Picolinamide derivatives as kinase inhibitors
MY165728A (en) Selective glycosidase inhibitors and uses thereof
TN2015000349A1 (en) CDC7 Inhibitors
MX354402B (es) Inhibidores de molecula pequeña del dominio de homologia de pleckstrin y metodos para usar los mismos.
MX339192B (es) Compuestos heterociclicos utiles para inhibicion de cinasa.
MX2007011859A (es) Compuestos mejorados farmacocineticamente.
EP2721033A4 (en) COMPOUNDS, PHARMACEUTICAL COMPOSITIONS AND THEIR USE AS IDH1 MUTANT INHIBITORS FOR THE TREATMENT OF CANCER
MX2010010209A (es) 4-hidroxipirimidina-5-carboxamidas sustituidas.
SI2350071T1 (sl) Substituirane pirazolo(1,5-a)pirimidinske spojine kot Trk kinazni inhibitorji
WO2010071846A3 (en) Compounds for treating neuropsychiatric conditions
EA201200323A1 (ru) Соединения и композиции, как ингибиторы протеинкиназы
ZA201102520B (en) Pyridine and pyrimidine based compounds as wnt signaling pathway inhibitors for the treatment of cancer
PH12020500072A1 (en) Heterocyclic inhibitors of atr kinase
AU2011278832A8 (en) Novel fused heterocyclic derivatives useful as c-Met tyrosine kinase inhibitors
MX2012004780A (es) Inhibidores de akt.
EA201491647A1 (ru) Основанные на арилэфирах ингибиторы киназ
MX2015000980A (es) Inhibidores de aril lactama cinasa.
IN2014CN04050A (es)
WO2007146813A3 (en) Pyridinone analogs as cell proliferation inhibitors

Legal Events

Date Code Title Description
FA Abandonment or withdrawal